Patent ductus arteriosus ligation versus medical therapy: A glowing recommendation for matching

Anusha Jegatheeswaran, MD, PhD, and Tara Karamlou, MD, MSc

In this month’s article by Mashally and colleagues,1 they attempt to answer the question: What outcomes are associated with oral acetaminophen therapy, in comparison with immediate surgical ligation (as defined by the authors) in neonates with persistent patent ductus arteriosus (PDA). The authors performed a retrospective, noncontemporaneous comparison of 43 patients who underwent immediate surgical ligation in an earlier era with 49 patients who were treated with acetaminophen, in whom surgery was restricted to those who failed medical therapy in the later era. The prevalence of crossover to surgical ligation in the later era occurred in the majority (53% of patients). Controversy exists regarding optimum mode of therapy, indications, and timing of surgical intervention, and the authors should be congratulated on investigating this important question in our field.2 The fallibility of medical therapy is that it may be ineffective, thus delaying the resolution of the hemodynamic compromise associated with a large PDA, resulting in a decline in the health status of the infant.2 Conversely, the surgical complications of PDA ligation are relatively rare, with immediate benefits.

The study has merit, insofar as it suggests a potential paradigm shift in care pathways for this challenging population that may reduce the need for surgical intervention. Unfortunately, there are several important limitations to the study that reduce its utility and impact.

The next issue that may magnify the impact of confounding by indication and suboptimal management of residual bias is that the authors have assigned morbidity (including chronic lung disease [CLD] and retinopathy of prematurity) to surgical ligation. Although previous studies have found that surgical ligation is associated with CLD, retinopathy of prematurity, and neurodevelopmental impairment in early childhood,3,4 we would contend that these reflect complications of prematurity in general and the natural history of this population. For instance, CLD in the setting of neonates with PDAs can be attributed to a prolonged period of pulmonary hypertension (exacerbated in patients in epoch 2). At the very least, these adverse outcomes could be due to the inherent inequality of the groups. Therefore, although we agree with the major finding of this study, “late acetaminophen therapy for infants with persistent PDA is associated with reduced exposure before treatment (12 vs 6 days, respectively). Intolerance to initial therapy with a cyclooxygenase-1 inhibitor was higher in epoch 2, and the treatment of lung disease of prematurity also evolved during the study period. In the absence of equipoise and a prospective randomized controlled trial, one avenue to mitigate confounding would be to use a propensity-matching algorithm (or even a propensity score) to account for the informative bias inherent in such nonrandomized comparisons.
surgical ligation but increased CLD,” the study design undermines the validity of this conclusion. More traditional complications associated with surgical ligation were infrequent in the study population, but tended to increase in the later era, which also may speak to the increased acuity in this group. Reviewing the available literature, the most recent study in a large, contemporary cohort by Weisz and colleagues ⁵ found that there was no difference in CLD or retinopathy of prematurity between medically or surgically managed preterm infants with PDA.

A final point to consider when interpreting the results of this study is that the dose of acetaminophen and the duration of treatment received by patients were variable. Therefore, it is unclear what the appropriate threshold would be for assigning a “failure” of medical therapy. Potential adoption or translation of the authors’ findings would be increased by elucidation of a standardized protocol that clearly delineates criteria for failure of medical therapy.

Currently, every neonatal intensivist and pediatric cardiac surgeon is faced with understanding the tradeoffs between persisting with medical therapy in the hopes of PDA closure and proceeding to surgical ligation with almost immediate effect. The study by Mashally and colleagues ¹ is important because it focuses attention on the notion that avoidance/delay of “invasive intervention,” although a laudable end point, may cause more detrimental outcomes, especially in a physiologically fragile population. Therefore, it is unfortunate that the design and execution of this study compromise the strength of the conclusions. Although the authors, in our opinion, have crossed the finish line, perhaps they haven’t played by all the rules.

References